Endocrinology, Vol 132, 61-66, Copyright © 1993 by Endocrine Society

ARTICLES

Characterization of the 1,25-(OH)2D3-induced inhibition of bone nodule formation in long-term cultures of fetal rat calvaria cells

H Ishida, CG Bellows, JE Aubin and JN Heersche
M.R.C. Group in Periodontal Physiology, Faculty of Dentistry, University of Toronto, Ontario, Canada.

We investigated the effects of 1,25-dihydroxyvitamin D3[1,25-(OH)2D3], on osteoprogenitor cell differentiation and bone nodule formation at various stages of differentiation by evaluating the effects on long term cultures of fetal rat calvaria (RC) cells. RC cells were plated at 3 x 10(4) cells/35-mm dish in alpha-minimal essential medium containing 15% fetal bovine serum, ascorbic acid, and beta-glycerophosphate (beta- GP), conditions under which bone nodules form. 1,25-(OH)2D3 inhibited bone nodule formation in a dose-dependent manner with total inhibition occurring at 1-10 nM and half-maximal inhibition occurring at approximately 0.06 nM. 1,25-(OH)2D3 also significantly stimulated RC cell growth in a dose-dependent manner in both the presence and absence of ascorbic acid. Addition of 1 nM 1,25-(OH)2D3 at different times after the start of culture inhibited nodule formation when added before and up to the early multilayering stage (up to day 11 of culture), but had no effect on nodule number when added later. When 1,25-(OH)2D3 was added at the start of the culture period and removed at the early multilayering stage, nodule formation was also inhibited. Pulses of 48- h duration also inhibited nodule formation, with maximal effect occurring between days 3 and 11. Thus, 1,25-(OH)2D3 inhibited osteoprogenitor cell differentiation during the earlier stages of culture before visible bone nodule formation occurred and the effect was not reversible upon removal of 1,25-(OH)2D3. In cultures grown to the multilayering stage in medium without ascorbic acid and beta-GP and then changed to medium with ascorbic acid and beta-GP, 1,25-(OH)2D3 inhibited when present before, but not after, the addition of ascorbic acid and beta-GP. Two other vitamin D3 metabolites, 24,25- dihydroxyvitamin D3 [24,25-(OH)2D3] and 1,24,25-trihydroxyvitamin D3 [1,24,25-(OH)3D3] had inhibitory effects similar to 1,25-(OH)2D3. The effects were dose dependent for each metabolite tested and correlated with the biological effectiveness of these metabolites in other systems: i.e. 1,25-(OH)2D3 was more effective than 1,24,25-(OH)3D3 which in turn was more effective than 24,25-(OH)2D3. The data show that 1,25-(OH)2D3 inhibits osteoprogenitor cell differentiation at an early stage and at a time during which cell growth is stimulated.

This article has been cited by other articles:

				J. A. Fretz, L. A. Zella, S. Kim, N. K. Shevde, and J. W. Pike 1,25-Dihydroxyvitamin D3 Regulates the Expression of Low-Density Lipoprotein Receptor-Related Protein 5 via Deoxyribonucleic Acid Sequence Elements Located Downstream of the Start Site of Transcription Mol. Endocrinol., September 1, 2006; 20(9): 2215 - 2230. [Abstract] [Full Text] [PDF]

				S. Zhang, M. Chan, and J. E Aubin Pleiotropic effects of the steroid hormone 1,25-dihydroxyvitamin D3 on the recruitment of mesenchymal lineage progenitors in fetal rat calvaria cell populations. J. Mol. Endocrinol., June 1, 2006; 36(3): 425 - 433. [Abstract] [Full Text] [PDF]

				A. Gurlek, M. R. Pittelkow, and R. Kumar Modulation of Growth Factor/Cytokine Synthesis and Signaling by 1{alpha},25-Dihydroxyvitamin D3: Implications in Cell Growth and Differentiation Endocr. Rev., December 1, 2002; 23(6): 763 - 786. [Abstract] [Full Text] [PDF]

				E. M. GARDINER, P. A. BALDOCK, G. P. THOMAS, N. A. SIMS, N. K. HENDERSON, B. HOLLIS, C. P. WHITE, K. L. SUNN, N. A. MORRISON, W. R. WALSH, et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage FASEB J, October 1, 2000; 14(13): 1908 - 1916. [Abstract] [Full Text]

				T. E. Johnson, R. Vogel, S. J. Rutledge, G. Rodan, and A. Schmidt Thiazolidinedione Effects on Glucocorticoid Receptor-Mediated Gene Transcription and Differentiation in Osteoblastic Cells Endocrinology, July 1, 1999; 140(7): 3245 - 3254. [Abstract] [Full Text]

				B. Ecarot and M. Desbarats 1,25-(OH)2D3 Down-Regulates Expression of Phex, a Marker of the Mature Osteoblast Endocrinology, March 1, 1999; 140(3): 1192 - 1199. [Abstract] [Full Text]

				G. F. MUSCHLER, C. BOEHM, and K. EASLEY Aspiration to Obtain Osteoblast Progenitor Cells from Human Bone Marrow: The Influence of Aspiration Volume J. Bone Joint Surg. Am., November 1, 1997; 79(11): 1699 - 1709. [Abstract] [Full Text]

				D. R. Ganta, M.-B. McCarthy, and G. A. Gronowicz Ascorbic Acid Alters Collagen Integrins in Bone Culture Endocrinology, September 1, 1997; 138(9): 3606 - 3612. [Abstract] [Full Text] [PDF]

				R. Zhang, P. Ducy, and G. Karsenty 1,25-Dihydroxyvitamin D3 Inhibits Osteocalcin Expression in Mouse through an Indirect Mechanism J. Biol. Chem., January 3, 1997; 272(1): 110 - 116. [Abstract] [Full Text] [PDF]